Abbott (ABT) Q2 2025 Earnings Call Transcript
Image source: The Motley Fool.
Need a quote from one of our analysts? Email [email protected]
Abbott Laboratories (NYSE:ABT) presented a quarter marked by distinct segment divergence, with medical devices sustaining double-digit organic sales growth and diagnostics constrained by COVID test declines and policy headwinds in China during Q2 2025 (non-GAAP). The company delivered high single-digit organic sales growth and margin expansion (non-GAAP) in the first half of 2025. New product milestones -- including regulatory approvals and clinical trial progress in cardiovascular and biosimilars -- indicate an acceleration of the innovation pipeline, while explicit FX forecasts offer refined visibility to investors.
Source Fool.com
Abbott Laboratories Stock
€114.16
-1.140%
The stock is an absolute favorite of our community with 34 Buy predictions and no Sell predictions.
With a target price of 127 € there is a slightly positive potential of 11.25% for Abbott Laboratories compared to the current price of 114.16 €.
